Stocks are trading with a cautious tone this morning as traders eye a key jobs report and additional economic data that could influence the Federal Reserve’s interest-rate path next year. Futures are all modestly lower in pre-market trading, with the Nasdaq under the greatest pressure amid lingering concerns around valuation in technology and AI-linked names. Record highs earlier in December have given way to a softer backdrop as investors weigh macro risk amid the release of delayed nonfarm payrolls and other indicators like retail sales and CPI inflation, which were postponed by the longest U.S. government shutdown in history.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Investors also continue to watch oil prices, which remain under pressure amid optimism about peace talks affecting supply dynamics.
In pre-market trading, S&P 500 futures fell 0.10%, Nasdaq futures fell 0.19% and Dow futures fell 0.05%.
Check out this morning’s top movers from around Wall Street, compiled by The Fly.
HIGHER –
- Organogenesis (ORGO) up 11% after completing a planned Type-B meeting with the FDA resulting in confirmation to initiate a rolling biologics licenses application for ReNu planned before the end of December
- Roku (ROKU) up 5% after Morgan Stanley double upgraded the stock to Overweight from Underweight with a price target of $135, up from $85
- Ford (F) up 1% after updating restructuring plans and increasing its full-year adjusted EBITDA guidance
- PayPal (PYPL) up 1% after filing an application to establish PayPal Bank
UP AFTER EARNINGS –
DOWN AFTER EARNINGS –
LOWER –
- Vital Farms (VITL) down 7% after cutting its FY25 revenue guidance ahead of its investor day
- Vestis (VSTS) down 1% after announcing departure of CFO Kelly Janzen
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
- Buy Rating for Organogenesis Holdings: FDA Progress and Favorable Policy Changes Drive Optimism
- Organogenesis plans to file BLA for ReNu before end of December
- Organogenesis price target raised to $9 from $7 at BTIG
- Organogenesis Holdings Surpasses Revenue Guidance Amid Challenges
- Organogenesis Holdings Reports Record Revenue, Raises Guidance